Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB080 in Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia
2022-501644-15-00Phase 2Withdrawn
- Sponsor
- Biogen
- Start
- Feb 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing BIIB080 with Placebo (2 arms). Primary endpoint: Dose-response in change from baseline to Week 76 on the CDR-SB. Planned start Feb 2023; status: withdrawn.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2022-501644-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501644-15-00.